Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prion protein interconversions.

B Caughey1

  • 1Laboratory of Persistent Viral Diseases, NIAID/NIH, Rocky Mountain Laboratories, Hamilton, MT 59840, USA. bcaughey@nih.gov

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|March 22, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS<sup>G12C</sup> inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cross-validation of the RT-QuIC assay for the antemortem detection of chronic wasting disease in elk.

Prion·2020
Same author

A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

Antimicrobial agents and chemotherapy·2017
Same author

Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).

Current molecular medicine·2015
Same author

Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?

Accounts of chemical research·2006
Same author

Prion protein and the molecular features of transmissible spongiform encephalopathy agents.

Current topics in microbiology and immunology·2004
Same journal

The microlandscapes of tree trunks: the effect of lichen and tree-level characteristics on arthropod communities.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same journal

Centimetre-scale landscapes to assess the motion behaviour and cognition of gastropods and bivalves.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same journal

Intertidal microcosms of wave-swept rocky shores: ecological and physiological insights from a uniquely stressful environment.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same journal

Temporal and spatial variation in temperature and oxygen at the microscale: key niche axes for aquatic life.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same journal

Natural microcosms in ecology: fulfilling the promise of model systems?

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
Same journal

Microbe-induced galls and plant defence: metabolite crosstalk in a co-evolutionary battle.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2026
See all related articles

Transmissible spongiform encephalopathies (TSEs) are mysterious neurodegenerative diseases. In vitro models reveal how prion protein (PrP) converts to a disease-associated form, aiding anti-TSE drug development.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Transmissible spongiform encephalopathies (TSEs), also known as prion diseases, are a group of fatal neurodegenerative disorders.
  • These diseases are characterized by the misfolding and aggregation of the prion protein (PrP).
  • The exact mechanisms of PrP conversion and propagation in vivo remain incompletely understood.

Purpose of the Study:

  • To summarize the use of in vitro models to study prion protein (PrP) conversion.
  • To elucidate the process by which PrP transforms into its disease-associated, protease-resistant form.
  • To identify potential therapeutic targets and lead compounds for anti-TSE drug development.

Main Methods:

  • Development and utilization of in vitro models that mimic key biological aspects of TSE diseases.

Related Experiment Videos

  • Characterization of PrP conversion using biochemical and biophysical techniques.
  • Screening for compounds that inhibit PrP conversion in vitro.

    • Main Results:

    • The in vitro models successfully replicate critical parameters of TSE pathogenesis.
    • The study provides insights into the structural changes and conversion process of PrP.
    • Inhibitors of PrP conversion were identified as promising lead compounds for drug discovery.

    Conclusions:

    • In vitro models are valuable tools for understanding prion protein conversion in TSEs.
    • These models facilitate the identification of therapeutic strategies against prion diseases.
    • Further development of anti-TSE drugs based on identified inhibitors is warranted.